Return to: Pharmaceutical News

Age-related Macular Degeneration Market Research Report, 2022

Age-related macular degeneration (AMD) is an acquired retinal disorder indicated by fundus changes. It is one of the most common forms of visual impairment in the geriatric population. It is a deterioration or degeneration of macular, leading to vision loss among people aged 60 years and above. The macula is a small part of retina responsible for sharpness and central vision.

Request Report Sample:

Smoking, obesity, high blood pressure, high cholesterol, poor diet, ultra-violet radiation, hereditary, and light eye color are some of the risk factors associated with AMD. In early stages, macular degeneration may not have symptoms, although with the progress of the disease it may have symptoms such as deterioration in central vision or dark spot, and blurriness.

Factors such as stringent regulatory requirements and increase in off label use are inhibiting the growth of the global market. The increasing awareness of AMD is the key trend observed in the global age-related macular degeneration market.

Explore Report with Detailed TOC at:

Some of the key companies operating in the global age-related macular degeneration market include Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Regeneron Pharmaceutical, Inc., Acucela, Ophthotech Corporation, Neurotech Pharmaceuticals, Inc., GlaxoSmithKline plc, StemCells Inc and Alimera Sciences, ...

News Release: Age-related Macular Degeneration Market Research Report, 2022
Submitted on: November 30, 2017 07:05:25 PM
Submitted by: vijay
On behalf of: